Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study

JAMA Psychiatry

Volumn 71, Issue 6, 2014, Pages 637-646

  Umbricht, Daniel ^a   Alberati, Daniela ^a   Martin Facklam, Meret ^a   Borroni, Edilio ^a   Youssef, Eriene A ^a   Ostland, Michael ^a   Wallace, Tanya L ^b,c   Knoflach, Frédéric ^a   Dorflinger, Ernest ^a   Wettstein, Joseph G ^a   Bausch, Alexander ^a   Garibaldi, George ^a   Santarelli, Luca ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b SRI INTERNATIONAL   (United States)

^c Support Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BITOPERTIN; CHOLESTEROL; GLUCOSE; GLYCINE TRANSPORTER 1; HEMOGLOBIN; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BARNES AKATHISIA SCALE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PLACEBO EFFECT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PR INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; PIPERAZINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULFONES; TREATMENT OUTCOME;

EID: 84900411478     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.163     Document Type: Article

References (53)

1. Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study. Schizophr Res. 2009;108 (1-3):223-230.
2. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505-511. (Pubitemid 351220787)
3. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359-369.
4. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495-506. (Pubitemid 40343916)
5. Gur RE, Kohler CG, Ragland JD, et al. Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull. 2006;32(2):279-287.
6. LambertM, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118(3):220-229.
7. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83(3-4):108-121.
8. Zukin SR, Zukin RS. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci U S A. 1979;76(10):5372-5376. (Pubitemid 10231634)
9. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug: sernyl. AMA Arch Neurol Psychiatry. 1959;81 (3):363-369.
10. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301-1308.
11. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214. (Pubitemid 24081509)
12. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry. 1998;43(11):811-816. (Pubitemid 28288379)
13. Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997;17(3):141-150. (Pubitemid 27365955)
14. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13(1):9-19.
15. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004; 185:196-204. (Pubitemid 39208220)
16. Vollenweider FX, GeyerMA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 2001;56 (5):495-507. (Pubitemid 34031785)
17. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 1988;241(4867):835-837.
18. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 1998;95(26):15730-15734. (Pubitemid 29018768)
19. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33 (4):1013-1022. (Pubitemid 47216643)
20. Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002;56(1-2):19-23. (Pubitemid 34655463)
21. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996; 153(12):1628-1630. (Pubitemid 26406177)
22. Heresco-Levy U, Javitt DC, ErmilovM, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996;169(5):610-617.
23. Heresco-Levy U, Javitt DC, ErmilovM, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56(1):29-36. (Pubitemid 29055047)
24. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994;151(8):1234-1236. (Pubitemid 24240973)
25. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44(11):1081-1089. (Pubitemid 28547143)
26. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451-460.
27. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196-1204. (Pubitemid 41586919)
28. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602. (Pubitemid 350069740)
29. Weiser M, Heresco-Levy U, Davidson M, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012; 73(6):e728-e734.
30. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006;(2):CD003730.
31. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia: a critical review and meta-analysis. Curr Pharm Des. 2010;16 (5):522-537.
32. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10):859-885.
33. Pinard E, Alanine A, Alberati D, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5- methanesulfonyl-2-((S)-2, 2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem. 2010;53(12):4603-4614.
34. Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152-1161.
35. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):225-230.
36. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.
37. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546. (Pubitemid 28100274)
38. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
39. Clinical Global Impression Scale. In: GuyW, ed. EDCEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, andWelfare; 1976:218-222.
40. Haro JM, Kamath SA, Ochoa S, et al SOHO Study Group. The Clinical Global Impression-Schizophrenia Scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003; 107(416):16-23.
41. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a newversion of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323-329. (Pubitemid 30173584)
42. Wilkinson G, Hesdon B, Wild D, et al. Self-report Quality of Life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177: 42-46. (Pubitemid 30450663)
43. Oxford Outcomes Ltd. The Revised Schizophrenia Quality of Life Questionnaire (SQLS-R4): User Manual for the SQLS-R4. Oxford, England: Oxford Outcomes; 2004.
44. Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery: CNS Vital Signs. Arch Clin Neuropsychol. 2006;21(7): 623-643. (Pubitemid 44754740)
45. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
46. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
47. Wong DF, Kuwabara H, Horti AG, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 2010;52(4):1505-1513.
48. Martin-Facklam M, Pizzagalli F, Zhou Y, et al. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology. 2013;38 (3):504-512.
49. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1995;166(1):68-72.
50. Loo H, Poirier-Littre MF, Theron M, ReinW, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18-22. (Pubitemid 27404772)
51. MartinaM, Gorfinkel Y, Halman S, et al. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol. 2004;557(pt 2):489-500. (Pubitemid 38807389)
52. Nong Y, Huang YQ, JuW, et al. Glycine binding primes NMDA receptor internalization. Nature. 2003;422(6929):302-307. (Pubitemid 36378356)
53. King PA, Gunn RB. Na- and Cl-dependent glycine transport in human red blood cells and ghosts: a study of the binding of substrates to the outward-facing carrier. J Gen Physiol. 1989;93(2): 321-342. (Pubitemid 19066824)